Cowen Reiterates Neutral Following Hortonworks (HDP) Q1 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
After-Hours Stock Movers 05/12: (HDP) (TUBE) (VRTX) Higher; (OREX) (VSLR) (GDDY) Lower (more...)
May 12, 2015 6:10 PM EDTFibrocell Science, Inc., (Nasdaq: FCSC) 18% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa (DEB), which includes RDEB.
Hortonworks (HDP) Tops Q1 EPS by 9c
May 12, 2015 4:02 PM EDTHortonworks (NASDAQ: HDP) reported Q1 EPS of ($0.77), $0.09 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $22 million versus the consensus estimate of $18.2 million.
For earnings history and earnings-related data on Hortonworks (HDP) click here.
... More